ACUTAASAcutaas Chemicals

₹1834.3+1.32%

Market Cap

₹14,991.83 Cr

Stock P/E

66.94

ROCE

20.14%

ROE

16.19%

Book Value

₹172.67

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Q1 FY26 shows solid top-line growth with improving margins and profitability.
•
PMDA GMP certification of Ankleshwar Unit II reinforces high-quality operations and compliance.

NEGATIVES

•
Pharma vs. Specialty margin gap could pressure overall margins if mix shifts unfavorably.
•
Execution and capex risks around battery additives and Indichem JV could delay revenue ramp; multiple capex milestones with tight timelines.

Peers Summary

Sector Laggard

Acutaas Chemicals Ltd. shows promising revenue growth but struggles with high valuation metrics compared to peers. The company is outperformed by several competitors in profitability and efficiency metrics, positioning it as a sector laggard despite its growth potential.

Key Points

• Acutaas Chemicals Ltd. has a high revenue growth rate but a high PE ratio, indicating overvaluation.
• Cipla Ltd. stands out as a value pick due to its low PE and high profitability.
• Divi's Laboratories Ltd. shows concerning growth patterns despite high margins.

Top Performers

Cipla Ltd.

Lowest PE at 23.73 and strong ROE of 16.63, marking it as a value pick with attractive profitability.

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with a PE of 15.50 and high ROE of 21.76, making it a strong overall performer.

Explore

Watchlists

Command Palette